Reinterventions in TAVR with Self-Expanding Valves

TAVR treatment of severe aortic stenosis is becoming more and more common, showing comparable evolution, or even superior in some studies when using the femoral approach, vs. surgical aortic valve replacement (SAVR).

stent

One of the current challenges is TAVR durability vs. SAVR. Even though 9 or 10 years has been deemed acceptable by current standards, we should not overlook the fact that there is a group of patients that will require reintervention, a scenario that we have not yet looked at in depth, let alone compared against surgery, which most likely will eventually be addressed. 

This was a retrospective analysis of the CoreValve US Pivotal Extreme-Risk, High-Risk and SURTAVI trials, including 7,757 patients: 5,925 undergoing TAVR (4,478 CoreValve and 1,447 Evolute R/PRO) and 1,832 SVAR.

99 of these patients (1.3%) required reintervention; 80 were treated with TAVR (69 CoreValve and 11 Evolut R/PRO).

Read also: 12-Month Evolution of Edge-to-Edge Repair with PASCAL.

At 5 year followup, 99 patients (1.3%) needed reinterventions, most frequently TAVR patients (2.2% vs. 1.5%; P=0.017) vs SVAR. Reinterventions were more common during the first year (<1 year; adjusted subdistribution HR: 3.50; CI 95%: 1.53-8.02), but there were no differences between years 1 and 5 (adjusted subdistribution HR: 1.05; CI 95%: 0.48-2.28). The main cause behind reintervention in TAVR patients were regurgitations and in SAVR patients, endocarditis. 

At 5 years, Evolut R/PRO presented a lower reintervention rate vs. CoreValve (0.9% vs. 1.6%; P=0.006), but there were no differences with SVAR (0.9% vs. 1.5%; P=0.41).

Conclusion

There was a lower reintervention rate for CoreValve/Evolut R/PRO and SVAR. Reinterventions were more frequent within the first year in TAVR patients and after the first year in SAVR patients. There were more reinterventions with first generation TAVR, CoreValve, and they were solved percutaneously. Reinterventions were more frequent with CoreValve than Evolut or SVAR.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Reinterventions After CoreValve/Evolut Transcatheter or Surgical Aortic Valve Replacement for Treatment of Severe Aortic Stenosis. 

Reference: Kendra J. Grubb, et al. J Am Coll Cardiol Intv 2024;17:1007–1016.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...